Seshadri P, Emerson L, Morales A
Department of Urology, Queen's University, Kingston, Ontario, Canada.
Urology. 1994 Oct;44(4):614-6. doi: 10.1016/s0090-4295(94)80074-x.
To assess the effect of the H2-antagonist cimetidine in the treatment of patients with interstitial cystitis (IC) refractory to other conservative therapies.
A group of 9 patients previously treated conservatively for IC without success were entered in the study. They were thoroughly investigated and treated with cimetidine at the dose of 300 mg orally twice a day for 1 month.
Six of the 9 patients (66%) experienced various degrees of symptomatic relief while on the drug. Of these, 4 (44%) have noted a complete and sustained response to the medication.
The encouraging results observed in this pilot study together with the simplicity and tolerance of the treatment makes it an alternative when other options have been exhausted. Its use as a first-line monotherapy remains speculative.
评估H2拮抗剂西咪替丁对其他保守治疗无效的间质性膀胱炎（IC）患者的治疗效果。
一组9名此前接受IC保守治疗但未成功的患者进入该研究。他们接受了全面检查，并以西咪替丁治疗，剂量为每日口服300毫克，分两次服用，持续1个月。
9名患者中有6名（66%）在服药期间症状得到不同程度缓解。其中4名（44%）对药物有完全且持续的反应。
在这项初步研究中观察到的令人鼓舞的结果，以及治疗的简易性和耐受性，使其在其他选择都已用尽时成为一种替代方案。将其用作一线单一疗法仍有待推测。
